FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

Nytt samarbete: Chat GPT flyttar in i Lundbecks laboratorier

Den danska läkemedelskoncernen Lundbeck tar hjälp av Open AI för att påskynda forskning och effektivisera arbetet inom hela verksamheten.

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS 2025 in Copenhagen.

Efficient use of blood plasma

Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Digitala produktpass - från regelverk till konkurrensfördel

Inom EU pågår just nu en omfattande omställning mot mer cirkulära och hållbara affärsmodeller. En viktig pusselbit i detta arbete är införandet av digitala prod...

Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.

How to transport hydrogen - the BionicHydrogenBattery

Have you ever wondered how hydrogen should be transported and stored safely. Well, here is a solution for all who is interested in making a true infrastructure work.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Conference recordings now available

Don't miss out on insights from leading experts.

FHM ska leda expertlabb för ebola och okända virussjukdomar

Folkhälsomyndigheten har fått ansvar för att driva det europeiska referenslaboratoriet för smittsamma sjukdomar som ebola, marburg och rabies. Uppdraget omfatta...

AI automates testing of implant coatings

The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect coated implants.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Cancer researcher: “We can do better and reduce suffering”

Lund University researcher Catharina Hagerling is developing innovative methods to understand metastatic cancer, aiming to create more targeted treatments for p...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Government apoints new experts to medicine and health council

Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

Cytel Sweden

Donanemab godkänns i Storbritannien – men anses för dyrt för skattebetalarna

Eli Lillys alzheimerläkemedel donanemab godkänns i Storbritannien – men lär ändå inte bli tillgängligt för vanliga patienter. Orsaken är att behandlingen bedöms...